GlycoMimetics Inc (GLYC)
0.416
+0.02
(+4.16%)
USD |
NASDAQ |
Nov 15, 16:00
0.42
0.00 (0.00%)
After-Hours: 20:00
GlycoMimetics Research and Development Expense (TTM): 22.89M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 22.89M |
| March 31, 2024 | 20.68M |
| December 31, 2023 | 20.07M |
| September 30, 2023 | 20.67M |
| June 30, 2023 | 20.31M |
| March 31, 2023 | 24.21M |
| December 31, 2022 | 28.39M |
| September 30, 2022 | 35.40M |
| June 30, 2022 | 43.75M |
| March 31, 2022 | 45.95M |
| December 31, 2021 | 47.49M |
| September 30, 2021 | 46.32M |
| June 30, 2021 | 43.70M |
| March 31, 2021 | 43.41M |
| December 31, 2020 | 44.93M |
| September 30, 2020 | 44.68M |
| June 30, 2020 | 44.73M |
| March 31, 2020 | 47.92M |
| December 31, 2019 | 47.03M |
| September 30, 2019 | 47.60M |
| June 30, 2019 | 46.61M |
| March 31, 2019 | 42.84M |
| December 31, 2018 | 40.09M |
| Date | Value |
|---|---|
| September 30, 2018 | 34.77M |
| June 30, 2018 | 30.82M |
| March 31, 2018 | 27.24M |
| December 31, 2017 | 24.10M |
| September 30, 2017 | 23.44M |
| June 30, 2017 | 23.58M |
| March 31, 2017 | 23.64M |
| December 31, 2016 | 23.28M |
| September 30, 2016 | 24.18M |
| June 30, 2016 | 23.30M |
| March 31, 2016 | 25.36M |
| December 31, 2015 | 25.05M |
| September 30, 2015 | 23.37M |
| June 30, 2015 | 23.38M |
| March 31, 2015 | 20.90M |
| December 31, 2014 | 19.57M |
| September 30, 2014 | 17.41M |
| June 30, 2014 | 15.31M |
| March 31, 2014 | 12.84M |
| December 31, 2013 | 11.70M |
| September 30, 2013 | 11.31M |
| June 30, 2013 | 10.81M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
20.07M
Minimum
Dec 2023
47.92M
Maximum
Mar 2020
36.45M
Average
43.70M
Median
Jun 2021
Research and Development Expense (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 779.92M |
| Arbutus Biopharma Corp | 62.79M |
| Revance Therapeutics Inc | 77.24M |
| FibroGen Inc | 185.40M |
| Cidara Therapeutics Inc | 70.46M |